Childhood spinal muscular atrophy (SMA) is a group of genetically determined diseases characterized by the loss of motor neurons located in the anterior horns of the spinal cord. This process results in progressive weakness and atrophy of skeletal muscles, which leads to limited mobility and a decrease in the quality of life of patients. The main focus in this pathology is on those forms that are linked to the X chromosome, which has a significant impact on the male sex. The disease occurs due to a mutation in the SMN1 (Survival Motor Neuron 1) gene, which leads to a deficiency of the SMN protein, critical for the survival and functioning of motor neurons.
History of the disease and interesting historical facts
Childhood spinal muscular atrophy was first described in the medical literature in the early 20th century. In 1891, German neurologist Wilhelm Hoffmann presented a case report that was later associated with the symptoms we associate with SMA today. In recent decades, the molecular genetics of the disease have become increasingly understood, thanks to advances in biochemistry and molecular biology. In 1995, the SMN1 gene was discovered, sparking an intense research effort to find treatments and diagnose SMA. Interestingly, in the 2000s, scientists began to hope for genetic therapies that could potentially slow or stop the progression of the disease, which eventually led to the development of the first drugs.
Epidemiology
Spinal muscular atrophy is recognized as one of the most common genetic diseases that cause muscle weakness in children. According to various estimates, the incidence of SMA is one in 6,000 to 10,000 newborns. Studies show that some of the highest incidence rates are recorded in certain ethnic groups, such as those with a high degree of inbreeding. It is important to note that the disease has an autosomal recessive type of inheritance, but in the case of X-linked forms, boys are predominantly affected, since they have only one X chromosome.
Genetic predisposition to this disease
Childhood spinal muscular atrophy is caused by mutations in the SMN1 gene, which is located on chromosome 5 and plays a key role in the production of a specific protein necessary for the survival of motor neurons. Most patients with SMA have a deletion or mutation of this gene. The SMN2 variants found in most patients do not produce enough functional protein to compensate for the lack of SMN1. It is considered that the presence of one or more copies of SMN2 can affect the severity of the disease. Other disease-related mutations in the gene pathways of neurotrophic factors, which may play a role in the pathogenesis of SMA, are also mentioned in the literature.
Risk factors for the development of this disease
There are several factors that may increase the risk of developing childhood spinal muscular atrophy:
- Genetic predisposition: presence of SMN1 mutation carriers in the family.
- Parental age: Older fathers may have an increased risk of passing on a mutation associated with the advanced paternal effect.
- Geographical features: Some regions with a high degree of inbreeding have an increased incidence of the disease.
- Gender: Men tend to get sick more often than women.
Diagnosis of this disease
Diagnosis of spinal muscular atrophy is based on a combination of clinical evaluation, laboratory tests, and molecular genetic testing. Key symptoms include:
- Muscle weakness that progresses from an early age.
- Muscle atrophy, especially proximal ones such as the thighs and shoulders.
- Impaired coordination of movements and changes in reflexes.
- Deterioration of respiratory function, especially in the later stages.
Laboratory tests include biochemical tests that show an increase in creatine kinase levels, as well as electromyography, which reveals signs of weakening of the motor units. The next step involves molecular genetic testing to confirm the presence of mutations in the SMN1 gene. Radiological examinations can be used to exclude other diseases that cause similar symptoms. It is important to perform a differential diagnosis with other neurological disorders, such as myasthenia gravis and various forms of dystrophy.
Treatment
Treatment of childhood spinal muscular atrophy is currently aimed at replacing the function of the missing SMN protein and improving the quality of life of patients. The main treatments include:
- Treatment with drugs that increase SMN levels, such as solisertribepec and risdiplam.
- Physiotherapy to maintain muscle tone and improve functionality.
- Surgical intervention in the event of specific complications, such as spinal curvature.
Pharmacological treatment may also include supportive regimens aimed at improving respiratory function and eliminating complications associated with respiratory or microbial infections.
List of medications used to treat this disease
The key drugs used to treat SMA are:
- Zolgensma (Olinecept) is a gene therapy that delivers a copy of the SMN1 gene.
- Spinraza (Nasizurso) is a therapy that modifies SMN2 splicing, increasing levels of SMN protein.
- Risdiplam is an oral agent that improves SMN2 splicing.
Disease monitoring
Monitoring patients with childhood spinal muscular atrophy requires a comprehensive approach. Doctors recommend regular follow-up examinations to assess the progression of the disease and adapt therapy.
- Routine examinations by a neurologist, orthopedist and pulmonologist.
- Evaluation of respiratory and motor system functions using standard tests.
- The prognosis may vary depending on the form of the disease, but many patients have a preserved life expectancy into adulthood.
It is important to note that complications may include respiratory problems and infectious diseases, which can significantly reduce quality of life.
Age-related features of the disease
Spinal muscular atrophy can present in different age groups, and symptoms can vary greatly. In infants, the disease can manifest itself in the first months of life, with marked muscle weakness and difficulty achieving motor milestones. In older children and adolescents, the pathological process can vary considerably, and some patients may show better results regardless of the severity of the disease.
Questions and Answers
- How is childhood spinal muscular atrophy inherited?
The disease is inherited in an autosomal recessive manner, which means that both parents must be carriers of the SMN1 gene mutation. - Is it possible to predict the development of a disease in a newborn?
Yes, molecular genetic testing can determine the likelihood of a newborn having a mutation if both parents are carriers. - What are the main symptoms of spinal muscular atrophy?
The main symptoms include muscle weakness, skeletal muscle atrophy, impaired coordination and decreased respiratory function. - Is there an effective treatment for SMA?
Yes, today there are modern treatment methods, such as genetic therapies, which have proven effective in patients with SMA. - What is the prognosis for patients with spinal muscular atrophy?
Prognosis varies depending on the form of the disease, but many patients can reach adulthood with adequate treatment and monitoring.
